274 related articles for article (PubMed ID: 12642304)
1. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.
Kötter I; Zierhut M; Eckstein AK; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Meyer-Riemann W; Peter HH; Stübiger N
Br J Ophthalmol; 2003 Apr; 87(4):423-31. PubMed ID: 12642304
[TBL] [Abstract][Full Text] [Related]
2. Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis.
Kötter I; Zierhut M; Eckstein A; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Peter HH; Kanz L; Stübiger N
Adv Exp Med Biol; 2003; 528():521-3. PubMed ID: 12918755
[No Abstract] [Full Text] [Related]
3. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease.
Wechsler B; Bodaghi B; Huong DL; Fardeau C; Amoura Z; Cassoux N; Piette JC; LeHoang P
Ocul Immunol Inflamm; 2000 Dec; 8(4):293-301. PubMed ID: 11262659
[TBL] [Abstract][Full Text] [Related]
4. Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.
Kötter I; Eckstein AK; Stübiger N; Zierhut M
Br J Ophthalmol; 1998 May; 82(5):488-94. PubMed ID: 9713053
[TBL] [Abstract][Full Text] [Related]
5. [Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a].
Deuter CM; Kötter I; Günaydin I; Zierhut M; Stübiger N
Ophthalmologe; 2004 Feb; 101(2):129-34. PubMed ID: 14991308
[TBL] [Abstract][Full Text] [Related]
6. Multifocal ERG changes in patients with ocular Behçet's disease during therapy with interferon alpha 2a.
Stübiger N; Besch D; Deuter CM; Zierhut M; Kötter I
Adv Exp Med Biol; 2003; 528():529-32. PubMed ID: 12918757
[No Abstract] [Full Text] [Related]
7. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.
Park JY; Chung YR; Lee K; Song JH; Lee ES
Yonsei Med J; 2015 Jul; 56(4):1158-62. PubMed ID: 26069144
[TBL] [Abstract][Full Text] [Related]
8. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial.
Kötter I; Vonthein R; Zierhut M; Eckstein AK; Ness T; Günaydin I; Grimbacher B; Blaschke S; Peter HH; Stübiger N
Semin Arthritis Rheum; 2004 Apr; 33(5):311-9. PubMed ID: 15079762
[TBL] [Abstract][Full Text] [Related]
9. Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behcet's disease: longitudinal study of up to 10 years.
Davatchi F; Sadeghi Abdollahi B; Shams H; Shahram F; Nadji A; Chams-Davatchi C; Faezi T; Akhlaghi M; Ghodsi Z; Ashofteh F; Mohtasham N
Int J Rheum Dis; 2014 May; 17(4):444-52. PubMed ID: 24314325
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis.
Onal S; Kazokoglu H; Koc A; Akman M; Bavbek T; Direskeneli H; Yavuz S
Arch Ophthalmol; 2011 Mar; 129(3):288-94. PubMed ID: 21402983
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate in ocular manifestations of Behcet's disease: a longitudinal study up to 15 years.
Davatchi F; Shams H; Shahram F; Nadji A; Chams-Davatchi C; Sadeghi Abdollahi B; Faezi T; Akhlaghi M; Ashofteh F
Int J Rheum Dis; 2013 Oct; 16(5):568-77. PubMed ID: 24164845
[TBL] [Abstract][Full Text] [Related]
12. [Behçet's disease: uveitis-therapy with interferon alpha2a - prospective clinical study in 33 patients].
Stübiger N; Kötter I; Deuter C; Zierhut M
Klin Monbl Augenheilkd; 2001 Dec; 218(12):768-73. PubMed ID: 11805868
[TBL] [Abstract][Full Text] [Related]
13. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis.
Plskova J; Greiner K; Forrester JV
Am J Ophthalmol; 2007 Jul; 144(1):55-61. PubMed ID: 17601428
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Adamantiades-Behçet disease with systemic interferon alfa.
Zouboulis CC; Orfanos CE
Arch Dermatol; 1998 Aug; 134(8):1010-6. PubMed ID: 9722733
[TBL] [Abstract][Full Text] [Related]
15. Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a.
Krause L; Altenburg A; Pleyer U; Köhler AK; Zouboulis CC; Foerster MH
J Rheumatol; 2008 May; 35(5):896-903. PubMed ID: 18412306
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients.
Bodaghi B; Gendron G; Wechsler B; Terrada C; Cassoux N; Huong du LT; Lemaitre C; Fradeau C; LeHoang P; Piette JC
Br J Ophthalmol; 2007 Mar; 91(3):335-9. PubMed ID: 17050581
[TBL] [Abstract][Full Text] [Related]
17. Behçet's disease: visual acuity after 5 years in patients with alpha-interferon treatment.
Deuter CM; Kötter I; Günaydin I; Zierhut M; Stübiger N
Adv Exp Med Biol; 2003; 528():525-8. PubMed ID: 12918756
[No Abstract] [Full Text] [Related]
18. Azathioprine and low dose pulse cyclophosphamide in severe ocular lesions of Behçet's disease. A preliminary report.
Shahram F; Davatchi F; Chams H; Nadji A; Jamshidi A; Akbarian M; Gharibdoost F
Adv Exp Med Biol; 2003; 528():571-3. PubMed ID: 12918767
[No Abstract] [Full Text] [Related]
19. Results of interferon alpha-2a therapy in patients with Behcet's disease.
Yalçindağ FN; Uzun A
J Ocul Pharmacol Ther; 2012 Aug; 28(4):439-43. PubMed ID: 22455657
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments.
Sobaci G; Erdem U; Durukan AH; Erdurman C; Bayer A; Köksal S; Karagul S; Bayraktar MZ
Ophthalmology; 2010 Jul; 117(7):1430-5. PubMed ID: 20417563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
